EP
NEPH icon

Elkhorn Partners’s Nephros NEPH Stock Holding History

Elkhorn Partners’s Portfolio NEPH Stock Details NEPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$39.3K Sell
11,000
-1,000
-8% -$3.25K 0.03% 41
2026
Q1 		$35.8K Buy
12,000
+5,000
+71% +$20K 0.02% 39
2025
Q4 		$34.2K Sell
7,000
-5,500
-44% -$28.1K 0.02% 35
2025
Q3 		$59.1K Sell
12,500
-2,000
-14% -$7.85K 0.04% 30
2025
Q2 		$59.3K Sell
14,500
-24,424
-63% -$65.2K 0.04% 30
2025
Q1 		$67K Sell
38,924
-2,505
-6% -$3.93K 0.04% 28
2024
Q4 		$61K Buy
41,429
+4,988
+14% +$7.6K 0.04% 32
2024
Q3 		$62K Buy
36,441
+441
+1% +$872 0.04% 38
2024
Q2 		$76K Hold
36,000
– – 0.05% 32
2024
Q1 		$79K Buy
36,000
+4,100
+13% +$13K 0.06% 32
2023
Q4 		$110K Sell
31,900
-13,441
-30% -$29.3K 0.08% 26
2023
Q3 		$67K Hold
45,341
– – 0.04% 37
2023
Q2 		$70K Sell
45,341
-5,000
-10% -$7.38K 0.04% 36
2023
Q1 		$54K Hold
50,341
– – 0.04% 34
2022
Q4 		$58K Hold
50,341
– – 0.04% 28
2022
Q3 		$46K Buy
50,341
+16,341
+48% +$23.1K 0.03% 33
2022
Q2 		$52K Buy
34,000
+10,288
+43% +$27.8K 0.03% 35
2022
Q1 		$104K Buy
23,712
+8,512
+56% +$40.4K 0.06% 28
2021
Q4 		$90K Buy
15,200
+6,700
+79% +$48.9K 0.05% 29
2021
Q3 		$75K Hold
8,500
– – 0.05% 32
2021
Q2 		$86K Sell
8,500
-5,519
-39% -$46K 0.05% 29
2021
Q1 		$93K Sell
14,019
-271
-2% -$2.14K 0.06% 25
2020
Q4 		$123K Sell
14,290
-1,410
-9% -$9.52K 0.08% 24
2020
Q3 		$114K Buy
15,700
+2,743
+21% +$20.1K 0.09% 28
2020
Q2 		$109K Hold
12,957
– – 0.08% 29
2020
Q1 		$82K Buy
12,957
+7,049
+119% +$59.8K 0.07% 30
2019
Q4 		$59K Buy
+5,908
New +$52.6K 0.03% 34

Other funds holding NEPH

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
CC
Cornerstone Capital Palo Alto, California $1.12B AUM 28.84% 1-Year Est. Return
BA
Bard Associates Chicago, Illinois $451M AUM 66.6% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
MFIM
Mesirow Financial Investment Management Chicago, Illinois $6.37B AUM 23.22% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return
NA
Navellier & Associates Reno, Nevada $1.26B AUM 95.39% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Elkhorn Partners's NEPH Position: Q2 2026 in Review

Elkhorn Partners reduced its Nephros (NEPH) stake by 8.3% in Q2 2026, selling an estimated $3.25K and leaving 11,000 shares worth $39.3K. The position accounts for 0.03% of the portfolio, ranked #41.

Elkhorn Partners first reported a position in NEPH in Q4 2019 and has held it in 27 quarters since. The position peaked at $123K in Q4 2020. 29 funds tracked by Wall St. Rank hold NEPH as of Q2 2026.

  • Elkhorn Partners held 11,000 shares of Nephros worth $39.3K as of Q2 2026.
  • Elkhorn Partners sold 1,000 Nephros shares in Q2 2026, an estimated $3.25K.
  • Nephros made up 0.03% of Elkhorn Partners's portfolio in Q2 2026, its #41 holding.
  • Elkhorn Partners first reported a position in Nephros in Q4 2019 and has held it in 27 quarters since.
  • Elkhorn Partners's Nephros position peaked at $123K in Q4 2020.
  • 29 funds tracked by Wall St. Rank held Nephros as of Q2 2026.

Based on Elkhorn Partners's 13F filing for Q2 2026, filed 13 Aug 2026.